The Treatment Action Campaign (TAC) supports the Union of India, Cancer Patients Aid Association & others in the case brought against them by the Swiss pharmaceutical company Novartis in relation to the interpretation of Section 3(d) of the Indian Patent Act.
6 September 2011
MSF supports the Cancer Patients Aid Association (CPAA) in its battle against Novartis. The CPAA is a party to this case and will be arguing for a strict interpretation of ‘efficacy’ so that patents on new forms of known medicines – such as the one on the cancer drug imatinib mesylate - are not granted routinely by Indian patent offices. Given the potential huge ramifications on generic production and the availability of affordable medicines from India, MSF, along with many other treatment providers, patient groups and affected communities is watching carefully the outcome of this case. Support the CPAA and the Lawyers Collective HIV/AIDS Unit, representing the CPAA in its battle to save section 3(d) and access to medicines across the developing world.